Evidence map›Paper›PMID 31327149›Full record

ReviewImmunologic research2019

Ocular mucous membrane pemphigoid: a review.

Samanta Taurone, Marialuisa Spoletini, Massimo Ralli, Pietro Gobbi, Marco Artico, Laszlò Imre, Cecília Czakò, Illés Kovàcs, Antonio Greco, Alessandra Micera

Abstract readReview
PubMed Publisher
In one paragraph

Review in Immunologic research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. [Paraneoplastic autoimmune dermatoses].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Samanta TauroneIRCCS - Fondazione Bietti, Rome, Italy.
Marialuisa SpoletiniDepartment of Sensory Organs, "Sapienza" University of Rome, V. le del Policlinico 155, 00161, Rome, Italy.
Massimo RalliDepartment of Sensory Organs, "Sapienza" University of Rome, V. le del Policlinico 155, 00161, Rome, Italy. massimo.ralli@uniroma1.it.ORCID http://orcid.org/0000-0001-8776-0421
Pietro GobbiDepartment of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, Italy.
Marco ArticoDepartment of Sensory Organs, "Sapienza" University of Rome, V. le del Policlinico 155, 00161, Rome, Italy.
Laszlò ImreDepartment of Ophthalmology, Semmelweis University, Budapest, Hungary.
Cecília CzakòDepartment of Ophthalmology, Semmelweis University, Budapest, Hungary.
Illés KovàcsDepartment of Ophthalmology, Semmelweis University, Budapest, Hungary.
Antonio GrecoDepartment of Sensory Organs, "Sapienza" University of Rome, V. le del Policlinico 155, 00161, Rome, Italy.
Alessandra MiceraIRCCS - Fondazione Bietti, Rome, Italy.
Policlinico Umberto I · ITSemmelweis University · HUFondazione G.B. Bietti · ITUniversity of Urbino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ocular mucous membrane pemphigoid (MMP) is a rare, immuno-mediated chronic progressive condition of the conjunctiva characterized by blisters developing from sub-epithelial tissue through disruption of the adhesions between the conjunctival epithelium and the sub-epithelium. Patients with ocular MMP, in many cases, develop profound conjunctival scarring and visual impairment. Furthermore, ocular MMP may lead to a progressive secondary corneal vascularization and to corneal opacification. Ocular MMP is difficult to diagnose during the initial stages because of false negatives during biopsy and variability in the clinical presentation. Most of the current pharmacological treatments aim to control the inflammatory response to reduce the progressive tissue remodeling which leads to the formation of a fibrotic scar. The course and prognosis of ocular MMP depend on the severity and progression of the disease after systemic immunomodulatory therapy. The aim of this review is to provide a comprehensive analysis of the current literature on established and emerging concepts in ocular MMP, with special attention to its clinical presentation, diagnosis, treatment, and pathogenic mechanisms, including the role of some cytokines and growth factors in the development of the disease.

Indexed as

BiomarkersConjunctivaConjunctivitisDisease ManagementDisease SusceptibilityHumansPemphigoid, Benign Mucous MembranePhenotypeSymptom AssessmentBiomarkersAutoimmune diseaseCytokinesFibrosisGrowth factorsMucous membrane pemphigoidOcular pemphigoid

Identifiers

PMID31327149
OpenAlexW2963439705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.